determining which cd19-directed car-t product is best for each patient with lbcl
Published 1 year ago • 99 plays • Length 2:01Download video MP4
Download video MP3
Similar videos
-
2:26
clinical data for cd19-directed car t-cell products in all
-
2:20
risk factors for success or failure of cd19-directed car-t therapy in children with b-all
-
1:33
patient selection for car-t in all
-
4:26
cd19-directed car-t in patients with r/r high-grade lymphoma
-
3:18
evaluating dual-targeting cd19/22 car-t cells in patients with r/r all
-
3:01
mechanisms of antigen escape following cd19-directed car-t therapy
-
0:45
bispecific car t-cell therapy: combining anti-cd19 and cd22 car t-cells
-
1:29
evaluating post-infusion car-treg cells to identify patients resistant to cd19 car-t therapy
-
1:59
efficacy and safety of cd19-targeted car t-cells for relapsed/refractory all
-
4:47
cd19 car t-cells for adults
-
3:06
repeat infusions of cd19 car-t
-
1:40
overcoming antigen escape following cd19-directed car-t therapy
-
1:26
emerging cd19-targeted car-t treatment approaches for nhls
-
3:07
the role of bridging and timing in car-t
-
1:21
anti-cd22 car t-cell therapy for all: trial update, utility for salvage and cd19 status
-
2:49
cd19 car-t therapy drives the expansion of clonal hematopoiesis and associated cytopenias in lbcl
-
4:24
key questions in the field of cd19 car t-cell therapy
-
4:21
mrd as a monitoring technique of allosct and car-t in aml/all
-
10:22
cd19 car-t in lymphoma patients in the uk